Tag: Aromasin
Articles
- Latest research concerning impact of endocrine therapy on breast cancer prognosis
- What should breast cancer survivors eat during aromatase inhibitor treatment?
News
- Aromatase inhibitor only or after tamoxifen are both effective treatments
- Aromatase inhibitors can increase risk of early hip fracture in breast cancer survivors
- Aromatase inhibitors can worsen cholesterol profile
- Aromatase inhibitors can worsen sexual function after breast cancer
- Aromatase inhibitors have numerous side effects in addition to musculoskeletal symptoms
- Increasingly severe side effects of aromatase inhibitors may make tamoxifen first the best strategy
- Tamoxifen treatment results in cognitive impairment compared to Aromasin
- Treatment with aromatase inhibitors results in better breast cancer outcomes than tamoxifen
- Vitamin D levels often low even in breast cancer survivors taking supplements
- Weight gain can increase hot flashes in breast cancer survivors on aromatase inhibitors
Studies
- Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
- Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial
- Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer
- Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2—3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study
- Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole
- Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial
- Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation
- Patient-Reported Predictors of Early Treatment Discontinuation: NCIC JMA.27/E1Z03 Quality of Life Study of Postmenopausal Women with Primary Breast Cancer Randomized to Exemestane or Anastrozole
- Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer
- Sexual Function after Breast Cancer
- Side effects associated with aromatase inhibitor treatment among breast cancer patients
- The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study
- Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
- Vitamin D Deficiency in Post-Menopausal Breast Cancer Survivors